查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1585840

支氣管擴張劑市場：按藥物類別、給藥途徑、疾病和最終用戶分類 - 全球預測 2025-2030

Bronchodilators Market by Drug Class (Anticholinergic Bronchodilators, Beta-Adrenergic Bronchodilators, Xanthine Derivative), Route of Administration (Injectable, Nasal, Oral), Disease, End-users - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

根據預測，2023年支氣管擴張劑市值為183.7億美元，預計2024年將達到192億美元，複合年成長率為5.98%，到2030年將達到275.9億美元。

市場區隔市場區隔是更廣泛的呼吸治療市場的一個重要部分，主要用於放鬆和拓寬肺部的氣道，改善氣流以及治療氣喘和慢性阻塞性肺病（用於放鬆的慢性阻塞性肺病）等疾病。支氣管擴張劑的需求是由於全球呼吸系統疾病的盛行率不斷上升，特別是環境污染、吸菸和工業事故發生率的上升。支氣管擴張劑的應用涵蓋多種給藥方式，包括吸入器、霧化器和口服藥物，以滿足急性和慢性治療需求。這些藥物有多種最終用途，從醫院的緊急治療到需要長期控制病情的患者的日常家庭使用。市場成長受到藥物輸送系統技術進步、意識增強以及針對個別患者情況客製化個人化醫療的需求的強烈影響。此外，發展中地區醫療基礎設施的興起帶來了潛在的擴張機會。關鍵的成長機會在於研究和開發新配方以減少副作用並提高效率，以及使用數位健康平台更好地監測和管理呼吸系統疾病。然而，市場並非沒有挑戰，嚴格的監管要求、高昂的開發成本以及長期使用相關的潛在副作用是主要障礙。生物療法等競爭治療方法也威脅市場佔有率。創新途徑是存在的，包括探索新型化合物、改善患者依從性技術以及整合人工智慧以提供預測性醫療服務。支氣管擴張劑市場的性質是高度動態的，大量持續的併購活動旨在加強產品平臺和策略性區域擴張，並不斷適應監管條件和消費者需求。

主要市場統計
基準年[2023] 183.7億美元
預測年份 [2024] 192億美元
預測年份 [2030] 275.9億美元
複合年成長率（%） 5.98%

市場動態：揭示快速發展的支氣管擴張劑市場的關鍵市場洞察

支氣管擴張劑市場正因供需的動態交互作用而轉變。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 全球呼吸系統疾病盛行率上升
    • 提高對氣喘和囊腫纖維化等呼吸系統疾病的認知
  • 市場限制因素
    • 治療慢性支氣管炎需要巨額費用
  • 市場機會
    • 積極開發新藥研究活動 支氣管擴張劑
    • 慢性支氣管炎治療的臨床試驗增加
  • 市場挑戰
    • 與服用支氣管擴張劑相關的副作用

波特的五力：駕馭支氣管擴張劑市場的策略工具

波特的五力架構是了解支氣管擴張劑市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解支氣管擴張劑市場的外部影響

外部宏觀環境因素在塑造支氣管擴張劑市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解支氣管擴張劑市場的競爭格局

支氣管擴張劑市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣支氣管擴張劑市場供應商的績效評估

FPNV定位矩陣是評估支氣管擴張劑市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，以確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議，繪製支氣管擴張劑市場的成功之路

對於旨在加強在全球市場的影響力的公司來說，支氣管擴張劑市場的策略分析至關重要。透過考慮關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監管核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 世界各地呼吸系統疾病的發生率正在上升
      • 提高對氣喘和囊腫纖維化等呼吸系統疾病的認知
    • 抑制因素
      • 治療慢性支氣管炎需要龐大資金
    • 機會
      • 旨在新開發的強力的研究活動
      • 治療慢性支氣管炎的臨床試驗增加
    • 任務
      • 與服用支氣管擴張劑相關的副作用
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章依藥物類別分類的支氣管擴張劑市場

  • 抗膽鹼能支氣管擴張劑
  • BETA-腎上腺素能支氣管擴張劑
  • 黃嘌呤衍生物

第7章支氣管擴張劑市場：依給藥途徑

  • 可注射的
  • 鼻腔
  • 口服

第8章支氣管擴張劑市場：依疾病分類

  • 氣喘
  • 慢性阻塞性肺病

第9章支氣管擴張劑市場：依最終用戶分類

  • 醫院
  • 專科診所

第10章美洲支氣管擴張劑市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太地區支氣管擴張劑市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章歐洲、中東和非洲支氣管擴張劑市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • AdvaCare Pharma
  • AMGIS Lifescience Ltd.
  • AstraZeneca PLC
  • Boehringer Ingelheim International GmbH
  • Cambrex Corporation
  • Catalent, Inc.
  • Cipla Limited
  • GlaxoSmithKline PLC
  • Glenmark Pharmaceuticals Limited
  • Hikma Pharmaceuticals PLC
  • Lupin Limited
  • Mylan Inc. by Viatris Inc.
  • Nephron Pharmaceuticals Corporation
  • Novartis AG
  • Perrigo Company PLC
  • Pfizer Inc.
  • Prasco Laboratories
  • Ralington Pharma LLP
  • Siemens Healthcare GmbH
  • Steris Healthcare Pvt. Ltd.
  • Sun Pharmaceutical Industries Limited
  • Teva Pharmaceutical Industries Ltd.
  • Thermo Fisher Scientific Inc.
  • Vectura Group PLC
  • Zydus Group
Product Code: MRR-C002B1C9948B

The Bronchodilators Market was valued at USD 18.37 billion in 2023, expected to reach USD 19.20 billion in 2024, and is projected to grow at a CAGR of 5.98%, to USD 27.59 billion by 2030.

Bronchodilators represent a critical segment within the broader respiratory therapeutics market, primarily used to relax and expand the air passages of the lungs, improving airflow and alleviating symptoms in conditions like asthma and COPD (Chronic Obstructive Pulmonary Disease). The necessity for bronchodilators stems from the increasing prevalence of respiratory disorders globally, particularly with the rising incidence of environmental pollution, smoking, and occupational hazards. The application of bronchodilators spans across various administration methods, including inhalers, nebulizers, and oral medications, catering to both acute and chronic therapeutic needs. These medications serve a diverse end-use scope, extending from emergency hospital care to routine home use by patients needing long-term management of their conditions. Market growth is strongly influenced by technological advancements in drug delivery systems, increased awareness, and demand for personalized medicine tailored to individual patient profiles. Additionally, rising healthcare infrastructure in developing regions presents a potential expansion opportunity. Key growth opportunities lie in the research and development of new formulations to reduce side effects and improve efficiency, as well as the exploitation of digital health platforms for better monitoring and management of respiratory conditions. However, the market is not without its challenges; stringent regulatory requirements, high development costs, and potential side effects associated with long-term use pose significant barriers. Competing treatment modalities, such as biological therapies, also threaten market share. Innovative avenues exist in the exploration of novel compounds, improvement of patient adherence technologies, and the integration of artificial intelligence for predictive healthcare delivery. The nature of the bronchodilator market is highly dynamic, marked by ongoing mergers and acquisitions aimed at product pipeline enhancement and strategic geographic expansion, necessitating continuous adaptation to regulatory landscapes and consumer demand.

KEY MARKET STATISTICS
Base Year [2023] USD 18.37 billion
Estimated Year [2024] USD 19.20 billion
Forecast Year [2030] USD 27.59 billion
CAGR (%) 5.98%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Bronchodilators Market

The Bronchodilators Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising prevalence of respiratory disorders worldwide
    • Growing awareness about asthma and cystic fibrosis respiratory disorders
  • Market Restraints
    • Huge expenditure required for treating chronic bronchitis
  • Market Opportunities
    • Robust research activities to develop noval bronchodilators
    • Increasing number of clinical trials to treat chronic bronchitis
  • Market Challenges
    • Side effects associated with consumption of bronchodilators

Porter's Five Forces: A Strategic Tool for Navigating the Bronchodilators Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Bronchodilators Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Bronchodilators Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Bronchodilators Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Bronchodilators Market

A detailed market share analysis in the Bronchodilators Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Bronchodilators Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Bronchodilators Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Bronchodilators Market

A strategic analysis of the Bronchodilators Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Bronchodilators Market, highlighting leading vendors and their innovative profiles. These include AdvaCare Pharma, AMGIS Lifescience Ltd., AstraZeneca PLC, Boehringer Ingelheim International GmbH, Cambrex Corporation, Catalent, Inc., Cipla Limited, GlaxoSmithKline PLC, Glenmark Pharmaceuticals Limited, Hikma Pharmaceuticals PLC, Lupin Limited, Mylan Inc. by Viatris Inc., Nephron Pharmaceuticals Corporation, Novartis AG, Perrigo Company PLC, Pfizer Inc., Prasco Laboratories, Ralington Pharma LLP, Siemens Healthcare GmbH, Steris Healthcare Pvt. Ltd., Sun Pharmaceutical Industries Limited, Teva Pharmaceutical Industries Ltd., Thermo Fisher Scientific Inc., Vectura Group PLC, and Zydus Group.

Market Segmentation & Coverage

This research report categorizes the Bronchodilators Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug Class, market is studied across Anticholinergic Bronchodilators, Beta-Adrenergic Bronchodilators, and Xanthine Derivative.
  • Based on Route of Administration, market is studied across Injectable, Nasal, and Oral.
  • Based on Disease, market is studied across Asthma and COPD.
  • Based on End-users, market is studied across Hospitals and Specialty Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of respiratory disorders worldwide
      • 5.1.1.2. Growing awareness about asthma and cystic fibrosis respiratory disorders
    • 5.1.2. Restraints
      • 5.1.2.1. Huge expenditure required for treating chronic bronchitis
    • 5.1.3. Opportunities
      • 5.1.3.1. Robust research activities to develop noval bronchodilators
      • 5.1.3.2. Increasing number of clinical trials to treat chronic bronchitis
    • 5.1.4. Challenges
      • 5.1.4.1. Side effects associated with consumption of bronchodilators
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Bronchodilators Market, by Drug Class

  • 6.1. Introduction
  • 6.2. Anticholinergic Bronchodilators
  • 6.3. Beta-Adrenergic Bronchodilators
  • 6.4. Xanthine Derivative

7. Bronchodilators Market, by Route of Administration

  • 7.1. Introduction
  • 7.2. Injectable
  • 7.3. Nasal
  • 7.4. Oral

8. Bronchodilators Market, by Disease

  • 8.1. Introduction
  • 8.2. Asthma
  • 8.3. COPD

9. Bronchodilators Market, by End-users

  • 9.1. Introduction
  • 9.2. Hospitals
  • 9.3. Specialty Clinics

10. Americas Bronchodilators Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Bronchodilators Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Bronchodilators Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AdvaCare Pharma
  • 2. AMGIS Lifescience Ltd.
  • 3. AstraZeneca PLC
  • 4. Boehringer Ingelheim International GmbH
  • 5. Cambrex Corporation
  • 6. Catalent, Inc.
  • 7. Cipla Limited
  • 8. GlaxoSmithKline PLC
  • 9. Glenmark Pharmaceuticals Limited
  • 10. Hikma Pharmaceuticals PLC
  • 11. Lupin Limited
  • 12. Mylan Inc. by Viatris Inc.
  • 13. Nephron Pharmaceuticals Corporation
  • 14. Novartis AG
  • 15. Perrigo Company PLC
  • 16. Pfizer Inc.
  • 17. Prasco Laboratories
  • 18. Ralington Pharma LLP
  • 19. Siemens Healthcare GmbH
  • 20. Steris Healthcare Pvt. Ltd.
  • 21. Sun Pharmaceutical Industries Limited
  • 22. Teva Pharmaceutical Industries Ltd.
  • 23. Thermo Fisher Scientific Inc.
  • 24. Vectura Group PLC
  • 25. Zydus Group

LIST OF FIGURES

  • FIGURE 1. BRONCHODILATORS MARKET RESEARCH PROCESS
  • FIGURE 2. BRONCHODILATORS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL BRONCHODILATORS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL BRONCHODILATORS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL BRONCHODILATORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL BRONCHODILATORS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL BRONCHODILATORS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL BRONCHODILATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL BRONCHODILATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL BRONCHODILATORS MARKET SIZE, BY DISEASE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL BRONCHODILATORS MARKET SIZE, BY DISEASE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL BRONCHODILATORS MARKET SIZE, BY END-USERS, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL BRONCHODILATORS MARKET SIZE, BY END-USERS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS BRONCHODILATORS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS BRONCHODILATORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES BRONCHODILATORS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES BRONCHODILATORS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC BRONCHODILATORS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC BRONCHODILATORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA BRONCHODILATORS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA BRONCHODILATORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. BRONCHODILATORS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. BRONCHODILATORS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. BRONCHODILATORS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL BRONCHODILATORS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL BRONCHODILATORS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL BRONCHODILATORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. BRONCHODILATORS MARKET DYNAMICS
  • TABLE 7. GLOBAL BRONCHODILATORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL BRONCHODILATORS MARKET SIZE, BY ANTICHOLINERGIC BRONCHODILATORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL BRONCHODILATORS MARKET SIZE, BY BETA-ADRENERGIC BRONCHODILATORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL BRONCHODILATORS MARKET SIZE, BY XANTHINE DERIVATIVE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL BRONCHODILATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL BRONCHODILATORS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL BRONCHODILATORS MARKET SIZE, BY NASAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL BRONCHODILATORS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL BRONCHODILATORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL BRONCHODILATORS MARKET SIZE, BY ASTHMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL BRONCHODILATORS MARKET SIZE, BY COPD, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL BRONCHODILATORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL BRONCHODILATORS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL BRONCHODILATORS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS BRONCHODILATORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS BRONCHODILATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS BRONCHODILATORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS BRONCHODILATORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS BRONCHODILATORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA BRONCHODILATORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA BRONCHODILATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA BRONCHODILATORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA BRONCHODILATORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL BRONCHODILATORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL BRONCHODILATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL BRONCHODILATORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL BRONCHODILATORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 34. CANADA BRONCHODILATORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA BRONCHODILATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA BRONCHODILATORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA BRONCHODILATORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 38. MEXICO BRONCHODILATORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 39. MEXICO BRONCHODILATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO BRONCHODILATORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO BRONCHODILATORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 42. UNITED STATES BRONCHODILATORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 43. UNITED STATES BRONCHODILATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES BRONCHODILATORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES BRONCHODILATORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES BRONCHODILATORS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 47. ASIA-PACIFIC BRONCHODILATORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 48. ASIA-PACIFIC BRONCHODILATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC BRONCHODILATORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC BRONCHODILATORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC BRONCHODILATORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 52. AUSTRALIA BRONCHODILATORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 53. AUSTRALIA BRONCHODILATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 54. AUSTRALIA BRONCHODILATORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA BRONCHODILATORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 56. CHINA BRONCHODILATORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 57. CHINA BRONCHODILATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 58. CHINA BRONCHODILATORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA BRONCHODILATORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 60. INDIA BRONCHODILATORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 61. INDIA BRONCHODILATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 62. INDIA BRONCHODILATORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA BRONCHODILATORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 64. INDONESIA BRONCHODILATORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 65. INDONESIA BRONCHODILATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 66. INDONESIA BRONCHODILATORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA BRONCHODILATORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 68. JAPAN BRONCHODILATORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 69. JAPAN BRONCHODILATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 70. JAPAN BRONCHODILATORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN BRONCHODILATORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 72. MALAYSIA BRONCHODILATORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 73. MALAYSIA BRONCHODILATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 74. MALAYSIA BRONCHODILATORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA BRONCHODILATORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 76. PHILIPPINES BRONCHODILATORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 77. PHILIPPINES BRONCHODILATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 78. PHILIPPINES BRONCHODILATORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES BRONCHODILATORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 80. SINGAPORE BRONCHODILATORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 81. SINGAPORE BRONCHODILATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 82. SINGAPORE BRONCHODILATORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE BRONCHODILATORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 84. SOUTH KOREA BRONCHODILATORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 85. SOUTH KOREA BRONCHODILATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH KOREA BRONCHODILATORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA BRONCHODILATORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 88. TAIWAN BRONCHODILATORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 89. TAIWAN BRONCHODILATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 90. TAIWAN BRONCHODILATORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN BRONCHODILATORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 92. THAILAND BRONCHODILATORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 93. THAILAND BRONCHODILATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 94. THAILAND BRONCHODILATORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND BRONCHODILATORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 96. VIETNAM BRONCHODILATORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 97. VIETNAM BRONCHODILATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 98. VIETNAM BRONCHODILATORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM BRONCHODILATORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA BRONCHODILATORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA BRONCHODILATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA BRONCHODILATORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA BRONCHODILATORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA BRONCHODILATORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 105. DENMARK BRONCHODILATORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 106. DENMARK BRONCHODILATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 107. DENMARK BRONCHODILATORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK BRONCHODILATORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 109. EGYPT BRONCHODILATORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 110. EGYPT BRONCHODILATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 111. EGYPT BRONCHODILATORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT BRONCHODILATORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 113. FINLAND BRONCHODILATORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 114. FINLAND BRONCHODILATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 115. FINLAND BRONCHODILATORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND BRONCHODILATORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 117. FRANCE BRONCHODILATORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 118. FRANCE BRONCHODILATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 119. FRANCE BRONCHODILATORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE BRONCHODILATORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 121. GERMANY BRONCHODILATORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 122. GERMANY BRONCHODILATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 123. GERMANY BRONCHODILATORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY BRONCHODILATORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 125. ISRAEL BRONCHODILATORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 126. ISRAEL BRONCHODILATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 127. ISRAEL BRONCHODILATORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL BRONCHODILATORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 129. ITALY BRONCHODILATORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 130. ITALY BRONCHODILATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 131. ITALY BRONCHODILATORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY BRONCHODILATORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 133. NETHERLANDS BRONCHODILATORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 134. NETHERLANDS BRONCHODILATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS BRONCHODILATORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS BRONCHODILATORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 137. NIGERIA BRONCHODILATORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 138. NIGERIA BRONCHODILATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 139. NIGERIA BRONCHODILATORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA BRONCHODILATORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 141. NORWAY BRONCHODILATORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 142. NORWAY BRONCHODILATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 143. NORWAY BRONCHODILATORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY BRONCHODILATORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 145. POLAND BRONCHODILATORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 146. POLAND BRONCHODILATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 147. POLAND BRONCHODILATORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND BRONCHODILATORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 149. QATAR BRONCHODILATORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 150. QATAR BRONCHODILATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 151. QATAR BRONCHODILATORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR BRONCHODILATORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 153. RUSSIA BRONCHODILATORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 154. RUSSIA BRONCHODILATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 155. RUSSIA BRONCHODILATORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA BRONCHODILATORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 157. SAUDI ARABIA BRONCHODILATORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 158. SAUDI ARABIA BRONCHODILATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA BRONCHODILATORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA BRONCHODILATORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 161. SOUTH AFRICA BRONCHODILATORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 162. SOUTH AFRICA BRONCHODILATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA BRONCHODILATORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA BRONCHODILATORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 165. SPAIN BRONCHODILATORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 166. SPAIN BRONCHODILATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 167. SPAIN BRONCHODILATORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN BRONCHODILATORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 169. SWEDEN BRONCHODILATORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 170. SWEDEN BRONCHODILATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 171. SWEDEN BRONCHODILATORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN BRONCHODILATORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 173. SWITZERLAND BRONCHODILATORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 174. SWITZERLAND BRONCHODILATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND BRONCHODILATORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND BRONCHODILATORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 177. TURKEY BRONCHODILATORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 178. TURKEY BRONCHODILATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 179. TURKEY BRONCHODILATORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY BRONCHODILATORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 181. UNITED ARAB EMIRATES BRONCHODILATORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 182. UNITED ARAB EMIRATES BRONCHODILATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES BRONCHODILATORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES BRONCHODILATORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED KINGDOM BRONCHODILATORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED KINGDOM BRONCHODILATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM BRONCHODILATORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM BRONCHODILATORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 189. BRONCHODILATORS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 190. BRONCHODILATORS MARKET, FPNV POSITIONING MATRIX, 2023